SiBone (SIBN)
(Delayed Data from NSDQ)
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
Zacks News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.
Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.
Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth
by Zacks Equity Research
Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.
Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.
What's in Store for Boston Scientific (BSX) in Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.
Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Si-Bone (SIBN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Walgreens (WBA) New Study Shows Medical Adherence Importance
by Zacks Equity Research
Walgreens' (WBA) latest research findings highlight the importance of patients adhering to their therapy.
Hologic (HOLX) Gains From New Launches as Macro Concerns Rise
by Zacks Equity Research
Hologic (HOLX) has been making impressive progress in its Breast Health arm, leveraging its strategic expansion efforts to diversify business across the patient continuum of care.
Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex
by Zacks Equity Research
The successful deployment of Abbott's (ABT) TactiFlex Ablation Catheter, Sensor Enabled in Canada broadens the company's global footprint in the electrophysiology space.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.
Abbott (ABT) Unveils Connected Diabetes App With New Pact
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre portfolio is the world's top sensor-based CGM system, changing the lives of over 5 million people.
Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities
by Zacks Equity Research
Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.
Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.
Phibro (PAHC) Sales Impacted by Macro Concerns, FX Headwind
by Zacks Equity Research
The COVID-19 pandemic has adversely affected the international economic conditions and financial markets, leading to an economic downturn in many countries, in which Phibro (PAHC) operates.
Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and stable liquidity.
Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures
by Zacks Equity Research
With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.